A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria:

• Histologically or cytologically confirmed diagnosis of unresectable Stage IIIb notamenable to treatment with combined modality chemoradiation (advanced) or Stage IV (metastatic) NSCLC

• Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2

• Measurable disease

• Adequate recovery from most recent systemic or local treatment for cancer

• Adequate organ function

• Life expectancy greater than or equal to (>/=) 12 weeks

• For female participants of childbearing potential and male participants, willingnessto use acceptable methods of contraception

Exclusion Criteria:

• Inability to swallow oral medication

• Women who are pregnant or lactating

• Symptomatic, untreated CNS metastases

• History of malignancy other than NSCLC within 5 years prior to screening with theexception of malignancies with negligible risk of metastasis or death

• Significant cardiovascular disease, such as New York Heart Association cardiacdisease (Class II or greater), myocardial infarction, or cerebrovascular accidentwithin 3 months prior to randomization, unstable arrhythmias, or unstable angina

• Known active or uncontrolled human immunodeficiency virus (HIV) infection

• Either a concurrent condition or history of a prior condition that places thepatient at unacceptable risk if he/she were treated with the study drug or confoundsthe ability to interpret data from the study

• Inability to comply with other requirements of the protocol